This Week’s CGT News: Novo’s Parkinson’s Pivot - Summary - MDSpire

This Week’s CGT News: Novo’s Parkinson’s Pivot

Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward

  • May 18, 2026

  • 7 min

Share

Objective:

To summarize recent advancements in gene therapy and cell therapy, particularly focusing on Parkinson's disease and other conditions.

Key Findings:
  • CAR-T therapy shows promise in targeting leukemia cells while sparing healthy cells.
  • Precision gene editing significantly reduces seizures in Dravet syndrome mouse models.
  • Prime editing effectively corrects genetic mutations linked to epilepsy.
  • New gene-editing technology allows for large DNA insertions, broadening treatment options.
  • MHRA's consultation aims to modernize gene therapy regulations in the UK.
  • Cellular Intelligence's acquisition may revitalize Parkinson's disease cell therapy development.
Interpretation:

These advancements highlight significant progress in gene and cell therapies, with potential implications for treating various genetic and neurodegenerative disorders.

Limitations:
  • Preclinical studies may not fully predict human outcomes.
  • Regulatory changes may take time to implement and affect development timelines.
Conclusion:

The landscape of gene and cell therapy is rapidly evolving, with promising new strategies and collaborations that may lead to effective treatments for challenging conditions.

Original Source(s)

This Week’s CGT News: Novo’s Parkinson’s Pivot

  • May 18, 2026

Related Content

Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min
This Week’s Biopharma News: FDA Commissioner Steps Down

Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.

  • May 19, 2026

  • 4 min
Three Trends Shaping Multi-omics Sample Preparation

Maximizing insight from limited samples, aligning data across molecular layers, and building consistency from the first step